Advertisement

Product › Details
cancer immunotherapy (immuno-oncology, I-O)
![]() |
Next higher product group | cancer drug |
![]() |
Status | 2012-10-06 |
Record changed: 2021-01-07 |
Advertisement

More documents for cancer immunotherapy (immuno-oncology, I-O)
- [1] T-Knife GmbH. (1/19/21). "Press Release: T-Knife Announces Appointment of Thomas M. Soloway as Chief Executive Officer and Camille A. Landis as Chief Business Officer & Chief Financial Officer". San Francisco, CA & Berlin....
- [2] Boehringer Ingelheim. (1/12/21). "Press Release: Boehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies". Ingelheim, Oxford & London....
- [3] Immunocore Ltd.. (1/11/21). "Press Release: Immunocore Announces Closing of $75.0 Million Series C Round". Oxfordshire, Conshohocken, PA & Rockville, MD....
- [4] Affimed N.V.. (1/11/21). "Press Release: Affimed Announces €25 Million Debt Financing Agreement with Silicon Valley Bank". Heidelberg....
- [5] Atomwise, Inc.. (12/18/20). "Press Release: Atomwise and FutuRx Launch A2i Therapeutics – a New Immuno-Oncology Company Funded by Leading Biopharma VCs and the Israeli Innovation Authority". San Francisco, CA & Ness Ziona....
- [6] Nouscom AG. (12/11/20). "Press Release: Nouscom Appoints Göran Ando MD as Chairman and Richard Davis PhD as Chief Business Officer". Basel....
- [7] Boehringer Ingelheim. (12/9/20). "Press Release: Boehringer Ingelheim to Acquire Labor Dr. Merk & Kollegen to Strengthen its Next Generation Cancer Immunology Program". Ingelheim & Ochsenhausen....
- [8] Novo Holdings A/S. (11/23/20). "Press Release: ISD Immunotech, a Novo Seeds Portfolio Company, Enters Strategic Research Collaboration for the Development of a Novel Lupus Treatment". Copenhagen....
- [9] Twist Bioscience Corporation. (10/13/20). "Press Release: Twist Bioscience and Neogene Announce Broad Strategic Partnership for Next Generation Personalized T Cell Therapies". South San Francisco, CA, Amsterdam & New York, NY....
- [10] Sensei Biotherapeutics, Inc.. (10/7/20). "Press Release: Sensei Biotherapeutics Announces $28.5 Million Financing To Advance Clinical Pipeline and Immunophage Platform Targeting Multiple Cancers". Boston, MA & Gaithersburg, MD....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top